Literature DB >> 15634714

Complementary secretagogue pairs unmask prominent gender-related contrasts in mechanisms of growth hormone pulse renewal in young adults.

Cacia Soares-Welch1, Leon Farhy, Kristi L Mielke, Farid H Mahmud, John M Miles, Cyril Y Bowers, Johannes D Veldhuis.   

Abstract

The present study examines the thesis that pulsatile GH secretion is controlled simultaneously by three principal signals; viz., GHRH, GH-releasing peptide (GHRP, ghrelin), and somatostatin (SS). According to this ensemble notion, no single regulatory peptide acts alone or can be interpreted in isolation. Therefore, to investigate gender-specific control of pulsatile GH secretion, we designed dual-effector stimulation paradigms in eight young men and six women as follows: 1) L-arginine/GHRH (to clamp low SS and high GHRH input); 2) L-arginine/GHRP-2 (to clamp low SS and high GHRP drive); 3) GHRH/GHRP-2 (to clamp high GHRH and high GHRP feedforward); vs. 4) saline (unclamped). Statistical comparisons revealed that: 1) fasting pulsatile GH secretion was 7.6-fold higher in women than men (P < 0.001); 2) L-arginine/GHRH and L-arginine/GHRP-2 evoked, respectively, 4.6- and 2.2-fold greater burst-like GH release in women than men (P < 0.001 and P = 0.015); and 3) GHRH/GHRP-2 elicited comparable GH secretion by gender. In the combined cohorts, estradiol concentrations positively predicted responses to L-arginine/GHRP-2 (r2= 0.49, P = 0.005), whereas testosterone negatively predicted those to L-arginine/GHRH (r2= 0.56, P = 0.002). Based upon a simplified biomathematical model of three-peptide control, the current outcomes suggest that women maintain greater GHRH potency, GHRP efficacy, and opposing SS outflow than men. This inference upholds recent clinical precedence and yields valid predictions of sex differences in self-renewable GH pulsatility.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15634714      PMCID: PMC1289271          DOI: 10.1210/jc.2004-1365

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  62 in total

1.  A feedback-controlled ensemble model of the stress-responsive hypothalamo-pituitary-adrenal axis.

Authors:  D M Keenan; J Licinio; J D Veldhuis
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Genomic structure and transcriptional regulation of the human growth hormone secretagogue receptor.

Authors:  S Petersenn; A C Rasch; M Penshorn; F U Beil; H M Schulte
Journal:  Endocrinology       Date:  2001-06       Impact factor: 4.736

3.  Short-term estradiol supplementation augments growth hormone (GH) secretory responsiveness to dose-varying GH-releasing peptide infusions in healthy postmenopausal women.

Authors:  S M Anderson; N Shah; W S Evans; J T Patrie; C Y Bowers; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

4.  Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.

Authors:  E Arvat; M Maccario; L Di Vito; F Broglio; A Benso; C Gottero; M Papotti; G Muccioli; C Dieguez; F F Casanueva; R Deghenghi; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  2001-03       Impact factor: 5.958

5.  Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth.

Authors:  M J Low; V Otero-Corchon; A F Parlow; J L Ramirez; U Kumar; Y C Patel; M Rubinstein
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

6.  A construct of interactive feedback control of the GH axis in the male.

Authors:  L S Farhy; M Straume; M L Johnson; B Kovatchev; J D Veldhuis
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-07       Impact factor: 3.619

7.  Gender and sexual maturation-dependent contrasts in the neuroregulation of growth hormone secretion in prepubertal and late adolescent males and females--a general clinical research center-based study.

Authors:  J D Veldhuis; J N Roemmich; A D Rogol
Journal:  J Clin Endocrinol Metab       Date:  2000-07       Impact factor: 5.958

8.  Growth hormone (GH) secretion in patients with an inactivating defect of the GH-releasing hormone (GHRH) receptor is pulsatile: evidence for a role for non-GHRH inputs into the generation of GH pulses.

Authors:  F Roelfsema; N R Biermasz; R G Veldman; J D Veldhuis; M Frölich; W H Stokvis-Brantsma; J M Wit
Journal:  J Clin Endocrinol Metab       Date:  2001-06       Impact factor: 5.958

9.  Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.

Authors:  L Gianotti; M Maccario; F Lanfranco; J Ramunni; L Di Vito; S Grottoli; E E Muller; E Ghigo; E Arvat
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

10.  Oral estradiol administration modulates continuous intravenous growth hormone (GH)-releasing peptide-2-driven GH secretion in postmenopausal women.

Authors:  N Shah; W S Evans; C Y Bowers; J D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2000-08       Impact factor: 5.958

View more
  4 in total

1.  Somatostatin and its receptors contribute in a tissue-specific manner to the sex-dependent metabolic (fed/fasting) control of growth hormone axis in mice.

Authors:  José Córdoba-Chacón; Manuel D Gahete; Justo P Castaño; Rhonda D Kineman; Raul M Luque
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-10-13       Impact factor: 4.310

2.  Hormone and genetic study in male to female transsexual patients.

Authors:  F Lombardo; L Toselli; D Grassetti; D Paoli; P Masciandaro; F Valentini; A Lenzi; L Gandini
Journal:  J Endocrinol Invest       Date:  2013-01-14       Impact factor: 4.256

3.  Novel relationships of age, visceral adiposity, insulin-like growth factor (IGF)-I and IGF binding protein concentrations to growth hormone (GH) releasing-hormone and GH releasing-peptide efficacies in men during experimental hypogonadal clamp.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Joy N Bailey; Adebordurin M Adeniji; John M Miles; Cyril Y Bowers
Journal:  J Clin Endocrinol Metab       Date:  2009-04-07       Impact factor: 5.958

Review 4.  Hypopituitarism following radiotherapy.

Authors:  Ken H Darzy; Stephen M Shalet
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.